- Public Library of Science
- Nature Magazine
- Vaccine
- Cell
- New England Journal of Medicine

Vaccine Development for SARS-CoV References by Journal 

- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
- Latin American Scientists Join the Coronavirus Vaccine Race

Articles on SARS-CoV Vaccine Development

A study showed that SARS neutralizing antibodies can successfully block SARS-CoV-2 entry into target cells in vitro, suggesting that the two viruses possess a cross-protective epitope and have similar immune protection against reinfection

SARS neutralizing antibodies and SARS-CoV-2


- PLOS ONE
- THE LANCET
- CDC
- New England Journal of Medicine (NEJM)
- Journal of Infectious Diseases
- Journal of Immunology
- JAMA Network
- MedRxiv

Antibody Immune Response for SARS-CoV References by Journal/ Source

- Philosophical transactions of the Royal Society of London. Series B, Biological sciences
- The Lancet

Epidemiology and Transmission Dynamics of SARS-CoV References by Journal

- The agent of SARS
- The first wave
- The second wave 
- Superspreader events
- Environment of SARS
- Transmission dynamics 

Epidemiology and Transmission Dynamics of SARS-CoV

- Vaccine Development
- Antibody immune response
- Epidemiology and transmission dynamics 

Syracuse University

Saint Louis University

University of Michigan - Ann Arbor

SARS-CoV, or SARS-associated coronavirus, is a virus that causes Severe Acute Respiratory Syndrome (SARS), which first appeared in 2003 and spread around the world. SARS-CoV is considered a select agent, meaning it has the potential to severely threathen public health.

SARS-CoV

This virus uses angiotensin-converting enzyme 2 (ACE2) as a functional cellular receptor.
The virus also binds to the C-type lectin CD209L (also known as L-SIGN) and DC-SIGN

Learn Before

Related

Learn After